DNA-Binding Fluorescent Dyes Detect Real-Time Cell Toxicity During Drug Screening

Spread the Word
Listed Under

Drug Development
High-throughput Screening
Beth Israel Medical Center


New Rochelle - New York - US


NEW ROCHELLE, N.Y. - May 30, 2014 - PRLog -- Contact: Vicki Cohn, Mary Ann Liebert, Inc., (914) 740-2100, ext. 2156, vcohn@liebertpub.com

DNA-Binding Fluorescent Dyes Detect Real-Time Cell Toxicity During Drug Screening

New Rochelle, NY—High throughput screening of compounds in live cells is a powerful approach for discovering new drugs, but the potential for cell toxicity must be considered. A novel technique that uses DNA-binding fluorescent dyes to evaluate the cytotoxicity of an experimental compound in real-time during screening, saving time and resources, is described in ASSAY and Drug Development Technologies, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the ASSAY and Drug Development Technologies website (http://www.liebertpub.com/adt).

Lucius Chiaraviglio and James Kirby, Beth Israel Deaconess Medical Center, evaluated 19 fluorescent DNA-binding dyes and identified four dyes that were not harmful to cells and could not cross the cell membrane if a cell was viable. The authors demonstrated the ability to use these dyes to detect cell death during drug screening in the article “Evaluation of Impermeant, DNA-Binding Dye Fluorescence as a Real-Time Readout of Eukaryotic Cell Toxicity in a High Throughput Screening Format.” (http://online.liebertpub.com/doi/full/10.1089/adt.2014.577)

About the Journal
Assay and Drug Development Technologies is an authoritative peer-reviewed journal published 10 times a year in print and online. It provides early-stage screening techniques and tools that enable identification and optimization of novel targets and lead compounds for new drug development. Complete tables of content and a complementary sample issue may be viewed on the ASSAY and Drug Development Technologies website (http://www.liebertpub.com/adt).

About the Publisher
Mary Ann Liebert, Inc., publishers
, is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many areas of science and biomedical research, including OMICS: A Journal of Integrative Biology and Genetic Testing and Molecular Biomarkers. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website (http://www.liebertpub.com).
Mary Ann Liebert, Inc., publishers PRs
Trending News
Top Daily News
Top Weekly News

Like PRLog?
Click to Share